Haleon to invest £130 million in global oral health innovation centre

This investment, referenced today by the UK Government as part of its International Investment Summit, demonstrates Haleon’s commitment to the UK as a leading global hub for life sciences, research and development (R&D) and innovation.

The 90,000 sq. ft building, built to the highest sustainability standards, is expected to open in 2027 and will be home to 450 employees. It will incorporate state-of-the-art and digitally enabled research laboratories alongside traditional workspaces and a dedicated consumer behavioural research facility. Together, these facilities will drive innovation across Haleon’s Oral Health portfolio, which includes Sensodyne, Polident/Poligrip, Aquafresh and Corsodyl.

Brian McNamara, CEO of Haleon, said: “Our decision to locate our Global Oral Health Innovation Centre in Weybridge reflects our confidence in the UK as a great place for a global company like ours to thrive. This facility is central to our efforts to attract and retain the best talent to fuel our growth and the continuous innovation which is so vital for delivering better everyday health. We support the UK Government’s ambition to drive future investment in the UK to cement its status as a leading centre for life sciences, R&D and innovation.”

Chancellor of the Exchequer, Rachel Reeves MP, said: “This investment is a huge vote of confidence in the UK’s life sciences sector, and is exactly the kind we want to see as we grow the economy. That’s what the International Investment Summit is all about too. Showing global investors and business that Britain is open for business”.

Media Contacts:

Gemma Thomas: [email protected]; +44 (0) 7721376006

Laura Hoy: [email protected]; +44 (0) 7554351990

Notes to Editors: Haleon’s Global Oral Health Innovation Centre

• Haleon’s Global Oral Health Innovation Centre will be built to the highest sustainability standards, with the aim of achieving a ‘BREEAM Outstanding’ rating, requiring an exceptional commitment to sustainability. 
• Responsible, locally sourced materials are at the heart of the design, while efforts to minimise energy and water consumption – such as a rain harvesting system – will support the site’s aim to achieve net zero carbon in operational energy. This will be complemented by a green travel plan which includes access to EV charging bays as well as cycling, pedestrian and public transport routes for colleagues. 
• Designed to create an accessible, inclusive and collaborative workspace, the site is also aiming to achieve the highest available ‘WELL’ rating to ensure a superior health and wellbeing experience for employees. The building will incorporate a variety of wellbeing areas, access, wayfinding systems and signage to accommodate a range of needs, as well as working environments which support neurodivergent employees.
• The history of the site’s location is steeped in innovation and engineering. Based in Brooklands Business Park, Weybridge, the area is renowned for being the birthplace of British motor racing, having formerly housed the world’s first purpose-built race circuit which opened in 1907. 
• Haleon has enjoyed a strong presence in Weybridge for 40 years, with its Beechams brand initially creating an R&D centre in the area in 1984. 

About Haleon: Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its longstanding brands - such as Sensodyne, Panadol, Otrivin, Polident, Corsodyl and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.